SPRY · ARS Pharmaceuticals, Inc.
$5.51
+0.00 (+0.00%)
At close · Aug 21
Market Cap
$547.46M
Shares
99.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.51
Open$5.52
Day$5.47–5.60
52W close$5.13–14.87
Avg vol 30d2.3M
Short int21.5M · 21.6% float · 7.8d
Short vol80%
Last earningsAug 13, 2026
DataDec 2020–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−24%
below
RSI (14)
39
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−40%
trailing
YTD return
−53%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
21.57% of float · ▼ -5.4% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
205 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
EPS growth
−2275%
Y/Y
Free cash flow
$-171.2M
Balance sheet
$55.1M
net debt
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 10, 2025
steady-state, long-term
Gross-to-net retention
at least 50%
steady-state
Gross-to-net retention
at least 50%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−24%
Bearish
RSI (14)
39
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +37 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
21.57% of float · ▼ -5.4% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
205 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $6 · 4%
Range high $15
vs 200-day avg -37%
vs 50-day avg -24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Collaboration revenue from international partners | $0.06M | FY2026 Q2 | -97.8% |
|
|
|||
| Market share among field-targeted accounts | 8% | the second quarter of 2026 | — |
| neffy U.S. net product revenue | $26.21M | FY2026 Q2 | +104.8% |
|
|
|||
| Supply revenue from partners | $7.39M | FY2026 Q2 | +2188.2% |
|
|
|||
| Total U.S. epinephrine market share | 5% | the second quarter of 2026 | — |
| U.S. net product revenue | $26.2M | Q2 2026 | +104.7% |
|
|
|||
| Unique prescribers | 16,000 | the second quarter of 2026 | — |
| Gross-to-net (GTN) | 50% | FY 2025 | — |
| Healthcare providers who have prescribed neffy to date | 28,000 | first quarter of 2026 | — |
| Repeat prescribers | 50% | FY 2025 | — |
| Retail cash option | $199 | FY 2025 | — |
| Sales force representatives and area sales managers | 148 | first quarter of 2026 | — |
| Schools opted into the neffyinSchools program | 10,000 | first quarter of 2026 | — |
| Successful uses of neffy reported in schools | 200 | first quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRY
this stock
ARS Pharmaceuticals, Inc.
|
$547.46M | -52.7% | -5.5% | — | 21.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRY | -2.6% | -7.3% | -40.0% | +7.3% | -52.8% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -1.2% | -11.0% | -51.5% | +4.8% | -65.0% |
Key facts
CIK
1671858
CUSIP
82835W108
13F (30d)
192 filings
189 filers
Visit website
Investor relations